Videos

Process of Administering Teclistamab and Other Bispecific Agents

February 15th 2023

A review of the process of “step-up” doses in teclistamab therapy for multiple myeloma and their use.

Guidelines for Opioid Use in Cancer Management are Needed, Expert Says

February 15th 2023

A review of the process of giving a patient a dose of teclistamab from start to finish.

Although opioid use guidelines from the Centers for Disease Control exclude patients with cancer, drug screenings are required that could further contribute to racial disparities.

Superiority of Asciminib in CML-CP Is a ‘Win-Win’ for Patients

February 14th 2023

Although opioid use guidelines from the Centers for Disease Control exclude patients with cancer, drug screenings are required that could further contribute to racial disparities.

Talha Badar, MBBS, MD, discussed the unmet needs in the treatment of chronic myeloid leukemia in chronic phase.

Kristie L. Kahl

February 14th 2023

Talha Badar, MBBS, MD, discussed the unmet needs in the treatment of chronic myeloid leukemia in chronic phase.

Review of Patient Subgroups in Transplant-Ineligible NDMM

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

Clinical Trials in Transplant-Ineligible NDMM

Oncology expert panelists review patient subgroup analyses for MAIA and SWOG0777 studies, investigating treatments for transplant-ineligible patients with newly diagnosed multiple myeloma.

Robert Z. Orlowski, MD, PhD;Amrita Y. Krishnan, MD;C. Ola Landgren, MD, PhD;Ajay K. Nooka, MD;Cesar Rodriguez, MD

Phase 3 ASCEMBL Study Demonstrates Superiority of Asciminib in CML-CP

Expert panelists review clinical data from studies investigating treatment regimens for patients with NDMM that are transplant-ineligible.

Talha Badar, MBBS, MD, discussed the results of the phase 3 ASCEMBL trial, demonstrating the superiority of asciminib versus bosutinib in patients with chronic myeloid leukemia in chronic phase.

Kristie L. Kahl

CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Additional Findings

Talha Badar, MBBS, MD, discussed the results of the phase 3 ASCEMBL trial, demonstrating the superiority of asciminib versus bosutinib in patients with chronic myeloid leukemia in chronic phase.

Brian I. Rini, MD;Hans Hammers, MD;Tian Zhang, MD;Moshe Ornstein, MD, MA

Non–BCMA-Targeting Bispecific Antibodies in R/R MM

Hans Hammers, MD, shares whether the updated CLEAR trial data would make him consider an IO-TKI regimen for patients with advanced RCC over an IO-IO regimen.

Sagar Lonial, MD, FACP;Sandy Wong, MD;Caitlin Costello, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD

CLEAR Trial of Lenvatinib + Pembrolizumab in Advanced RCC: Updated Efficacy Outcomes

A brief review of non–BCMA-targeted bispecific antibodies under investigation in patients with relapsed/refractory multiple myeloma.

Brian I. Rini, MD;Hans Hammers, MD;Tian Zhang, MD;Moshe Ornstein, MD, MA

BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Brian Rini, MD, presents updated data from the CLEAR trial of lenvatinib plus pembrolizumab versus sunitinib in frontline advanced renal cell carcinoma.

Sagar Lonial, MD, FACP;Sandy Wong, MD;Caitlin Costello, MD;Timothy Schmidt, MD;Samuel M. Rubinstein, MD

‘Multipronged Approach’ Necessary for Mitigating Opioid Disparities in Cancer

Expert perspectives on recent clinical data on BCMA-targeted bispecific antibody therapy in patients with relapsed/refractory multiple myeloma.

An expert from Dana-Farber Cancer Institute says that policymakers and insurers should take a hard look at policies that restrict opioid use in patients with cancer who are at end of life, especially for underserved communities.

Expert Seeks to Assess Opioid Access Disparities in Younger Cancer Population

February 12th 2023

An expert from Dana-Farber Cancer Institute says that policymakers and insurers should take a hard look at policies that restrict opioid use in patients with cancer who are at end of life, especially for underserved communities.

After assessing racial disparities in opioid access in older patients with cancer, an expert from Dana-Farber Cancer Institute speaks to the need for examining younger populations and those with different insurance types.

Treatment Strategies for Patients With Transplant-Ineligible NDMM

February 11th 2023

After assessing racial disparities in opioid access in older patients with cancer, an expert from Dana-Farber Cancer Institute speaks to the need for examining younger populations and those with different insurance types.

Beth Faiman, PhD, MSN, APN-BC;Sandra Mazzoni, MD;Jack Khouri, MD;Louis Williams, MD

Patient Case 2: Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Expert perspectives on selection of induction therapy for patients with transplant-ineligible newly diagnosed multiple myeloma.

Beth Faiman, PhD, MSN, APN-BC;Sandra Mazzoni, MD;Jack Khouri, MD;Louis Williams, MD

Considering a Patient with Colorectal Cancer for Adjuvant Chemotherapy

Panelists move on to review a patient case of transplant-ineligible newly diagnosed multiple myeloma and highlight clinical workup strategies.

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS

Patient Scenario: A 64-Year-Old Man with Stage II Colon Cancer

Aparna Parikh, MD, MS, details when she would recommend adjuvant chemotherapy to patients with similar presentations of colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP;Daniel H. Ahn, DO;Stacey A. Cohen, MD;Aparna Raj Parikh, MD, MS

Role of Venetoclax in Patients with High-Risk CLL

Tanios S. Bekaii-Saab, MD, presents a patient scenario of a 64-year-old man with stage 2 (pT3N0) colon cancer to the panel for discussion.

Susan O'Brien, MD;Alexey Danilov, MD, PhD;Seema Ali Bhat, MD;Catherine Coombs, MD

Fixed-Duration Venetoclax in the Treatment of CLL

Dr Catherine Coombs explains the challenges of treating 17p deletions and Richter’s syndrome in patients with CLL and discusses the role of venetoclax in the treatment of these patients.

Susan O'Brien, MD;Alexey Danilov, MD, PhD;Seema Ali Bhat, MD;Catherine Coombs, MD

Expert Highlights Gender/Racial Disparities in Opioid Access for Cancer Near End of Life

Seema Ali Bhat, MD, and Alexey Danilov, MD, PhD, discuss data updates on the use of fixed-duration venetoclax for the treatment of CLL.

An expert from Dana-Farber Cancer Institute states that although giving opioids for minor procedures could lead to substance abuse issues, use of the drugs to manage end of life cancer pain should not be up for debate.

Relapsed/Refractory Multiple Myeloma: Overview of Treatment Options

February 9th 2023

An expert from Dana-Farber Cancer Institute states that although giving opioids for minor procedures could lead to substance abuse issues, use of the drugs to manage end of life cancer pain should not be up for debate.

Melissa Alsina, MD;Rachid Baz, MD;Brandon Blue, MD;Ken Shain, MD, PhD

Patient Profile 2: Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Switching their focus to the relapsed/refractory setting, experts from the Moffit Cancer Center consider second-line treatment options for patients with multiple myeloma.

Melissa Alsina, MD;Rachid Baz, MD;Brandon Blue, MD;Ken Shain, MD, PhD

The Role of Teclistamab in Multiple Myeloma

Expert perspectives on a patient profile of transplant-ineligible multiple myeloma, with considerations for treatment selection and defining transplant ineligibility.

Patient Experience With Treatment for Multiple Myeloma and Clinical Trial Participation

Dr Ajai Chari explains the mechanism of action of BCMA-targeting bispecifics and the role of teclistamab in multiple myeloma treatment.

Expert Details ‘Pervasive’ Racial/Ethnic Opioid Access Disparities in Cancer

Anne-Marie Jacob describes her early treatment regimen for multiple myeloma and her experience with clinical trial enrollment.

An expert from Dana-Farber Cancer Institute discusses data from a study investigating racial inequities in opioid access among patients of cancer near the end of life.

Expert Highlights Need for Bias Training to Reduce Opioid Access Disparities in Cancer

February 7th 2023

An expert from Dana-Farber Cancer Institute discusses data from a study investigating racial inequities in opioid access among patients of cancer near the end of life.

An expert from Dana-Farber Cancer Institute describes several key strategies for mitigating racial disparities in opioid access among patients with cancer near end of life.